Abstract
Background: Radium-223 (223Ra) chloride, an alpha emitter, has been shown to improve overall survival (OS) and pain control, and to delay skeletal-related events, in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Our retrospective observational study presents the first Italian experience on the efficacy and safety of223Ra therapy in routine clinical practice. Methods: A total of 83 patients with metastatic CRPC were treated with223Ra at 3 Italian centers between August 2013 and August 2016.223Ra-chloride (55 kBq/kg) was administered every 4 weeks for a total of 6 cycles. Primary endpoints were OS and progression-free survival (PFS). Secondary endpoints included toxicity, pain evaluation using numeric rating scale (NRS), symptomatic skeletal-related events and biomarkers response. Results: Patients had a median age of 75 (range 53–89) years. The majority of men showed a Gleason score of 7, 8, or 9. Forty-one patients completed 6 treatment cycles; 33 stopped treatment before completing 6 cycles. Nine were still receiving therapy at the time of data collection. At the end of therapy, NRS pain scores significantly improved (p <.000001). OS was a mean of 10.1 months, while median OS had not been attained. According to Kaplan-Meier estimation, OS and PFS were 17.5 and 7.7 months, respectively. There was a significant correlation between OS and PFS with the number of223Ra cycles; patients receiving all 6 cycles experienced the major benefit from the therapy.223Ra was well-tolerated. Conclusions:223Ra alpha therapy is an important therapeutic option for men with CRPC and symptomatic skeletal metastases.
| Original language | English |
|---|---|
| Pages (from-to) | 128-136 |
| Number of pages | 9 |
| Journal | Tumori |
| Volume | 104 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Jan 1 2018 |
Fingerprint
Keywords
- Brachytherapy
- Hormone-refractory prostate cancer
- Neoplasm metastasis
- Radium
- prostate cancer
ASJC Scopus subject areas
- Medicine(all)
Cite this
223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases : Real-world experience. / Boni, Giuseppe; Mazzarri, Sara; Cianci, Claudia; Galli, Luca; Farnesi, Azzurra; Borsatti, Eugenio; Bortolus, Roberto; Fratino, Lucia; Gobitti, Carlo; Lamaj, Elda; Ghedini, Pietro; Rizzini, Elisa Lodi; Massari, Francesco; Dionisi, Valeria; Fanti, Stefano; Volterrani, Duccio; Monari, Fabio.
In: Tumori, Vol. 104, No. 2, 01.01.2018, p. 128-136.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - 223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases
T2 - Real-world experience
AU - Boni, Giuseppe
AU - Mazzarri, Sara
AU - Cianci, Claudia
AU - Galli, Luca
AU - Farnesi, Azzurra
AU - Borsatti, Eugenio
AU - Bortolus, Roberto
AU - Fratino, Lucia
AU - Gobitti, Carlo
AU - Lamaj, Elda
AU - Ghedini, Pietro
AU - Rizzini, Elisa Lodi
AU - Massari, Francesco
AU - Dionisi, Valeria
AU - Fanti, Stefano
AU - Volterrani, Duccio
AU - Monari, Fabio
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Background: Radium-223 (223Ra) chloride, an alpha emitter, has been shown to improve overall survival (OS) and pain control, and to delay skeletal-related events, in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Our retrospective observational study presents the first Italian experience on the efficacy and safety of223Ra therapy in routine clinical practice. Methods: A total of 83 patients with metastatic CRPC were treated with223Ra at 3 Italian centers between August 2013 and August 2016.223Ra-chloride (55 kBq/kg) was administered every 4 weeks for a total of 6 cycles. Primary endpoints were OS and progression-free survival (PFS). Secondary endpoints included toxicity, pain evaluation using numeric rating scale (NRS), symptomatic skeletal-related events and biomarkers response. Results: Patients had a median age of 75 (range 53–89) years. The majority of men showed a Gleason score of 7, 8, or 9. Forty-one patients completed 6 treatment cycles; 33 stopped treatment before completing 6 cycles. Nine were still receiving therapy at the time of data collection. At the end of therapy, NRS pain scores significantly improved (p <.000001). OS was a mean of 10.1 months, while median OS had not been attained. According to Kaplan-Meier estimation, OS and PFS were 17.5 and 7.7 months, respectively. There was a significant correlation between OS and PFS with the number of223Ra cycles; patients receiving all 6 cycles experienced the major benefit from the therapy.223Ra was well-tolerated. Conclusions:223Ra alpha therapy is an important therapeutic option for men with CRPC and symptomatic skeletal metastases.
AB - Background: Radium-223 (223Ra) chloride, an alpha emitter, has been shown to improve overall survival (OS) and pain control, and to delay skeletal-related events, in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Our retrospective observational study presents the first Italian experience on the efficacy and safety of223Ra therapy in routine clinical practice. Methods: A total of 83 patients with metastatic CRPC were treated with223Ra at 3 Italian centers between August 2013 and August 2016.223Ra-chloride (55 kBq/kg) was administered every 4 weeks for a total of 6 cycles. Primary endpoints were OS and progression-free survival (PFS). Secondary endpoints included toxicity, pain evaluation using numeric rating scale (NRS), symptomatic skeletal-related events and biomarkers response. Results: Patients had a median age of 75 (range 53–89) years. The majority of men showed a Gleason score of 7, 8, or 9. Forty-one patients completed 6 treatment cycles; 33 stopped treatment before completing 6 cycles. Nine were still receiving therapy at the time of data collection. At the end of therapy, NRS pain scores significantly improved (p <.000001). OS was a mean of 10.1 months, while median OS had not been attained. According to Kaplan-Meier estimation, OS and PFS were 17.5 and 7.7 months, respectively. There was a significant correlation between OS and PFS with the number of223Ra cycles; patients receiving all 6 cycles experienced the major benefit from the therapy.223Ra was well-tolerated. Conclusions:223Ra alpha therapy is an important therapeutic option for men with CRPC and symptomatic skeletal metastases.
KW - Brachytherapy
KW - Hormone-refractory prostate cancer
KW - Neoplasm metastasis
KW - Radium
KW - prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85050177913&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050177913&partnerID=8YFLogxK
U2 - 10.1177/0300891618765571
DO - 10.1177/0300891618765571
M3 - Article
C2 - 29714668
AN - SCOPUS:85050177913
VL - 104
SP - 128
EP - 136
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 2
ER -